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Abstract
The majority of familial noncompaction
cardiomyopathy (NCCM) is explained by
pathogenic variants in the same sarcomeric
genes that are associated with hypertrophic
(HCM) and dilated (DCM) cardiomyopa-
thy. Pathogenic variants in the filamin C
gene (FLNC) have been linked to HCM and
DCM. We expand the spectrum of FLNC
related cardiomyopathies by presenting two
families with likely pathogenic FLNC vari-
ants showing familial segregation of
NCCM and concurrent coarctation of the
aorta and/or mitral valve abnormalities. 
Introduction
Noncompaction cardiomyopathy
(NCCM) is characterized by excessive tra-
beculation of the left ventricle (LV) with a
noncompacted to compacted ratio of more
than 2 according to current echocardio-
graphic criteria, or 2.3 on CMR.1,2
Approximately 10% of patients diagnosed
with NCCM have concurrent congenital
heart defects (CHD).3,4
In 30-40% of cases diagnosed with
NCCM a pathogenic variant can be identi-
fied. Around 80% of these pathogenic vari-
ants involve the same sarcomere genes, that
are the major causes for hypertrophic car-
diomyopathy (HCM) and dilated cardiomy-
opathy (DCM), in particular MYH7,
MYBPC3 and TTN.5,6 Filamin C (FLNC)
plays a central role in muscle functioning
by maintaining the structural integrity of the
muscle fibers. Pathogenic variants in FLNC
were found to be associated with a wide
spectrum of myopathies ranging from car-
diomyopathies to distal skeletal
myopathies. Truncating FLNC variants
were previously associated with dilated car-
diomyopathy7-9 and missense variants were
identified in familial HCM and restrictive
cardiomyopathy. FLNC has not been associ-
ated with NCCM or CHD before.
We present two Dutch families where
familial NCCM with CHD were linked to
rare FLNC missense variants. These obser-
vations suggest that the spectrum of clinical
manifestations of FLNC variants include
familial NCCM with CHD.
Case Reports
Family A
In this family (Figure 1A), a 52-year-
old woman (II:3) was first diagnosed with
NCCM when she underwent cardiologic
examination for a suspected perimyocardi-
tis. Echocardiography showed pericardial
effusion and normal LV dimensions without
LV dysfunction. The LV walls showed
hypertrabeculation with end-systolic non-
compacted/compacted (NC/C) ratio >2.
Electrocardiographically, inferolateral repo-
larization abnormalities were observed.
Cardiac magnetic resonance imaging
(CMR) confirmed the diagnosis of NCCM
with diastolic NC/C ratio >2.3 in the LV
inferoseptal wall. She had elevated CK lev-
els of 1234 U/L [ref <200U/l]. No signs for
neuromuscular disease were detected at
neurologic examination. After seven years
of follow-up, she remained cardiologically
asymptomatic (NYHA class I).
Family screening revealed NCCM in
two relatives. A niece (III:3), was diagnosed
with NCCM at age 21 and had surgery at
age seven for coarctation of the aorta
(CoA). She fulfilled both the echocardiog-
raphy and CMR diagnostic criteria for
NCCM and had excessive long chordae of
the anterior mitral valve leaflet (Figure 2A
and B). The noncompaction had not been
recognized in the past on echocardiography.
Cardiologic screening of an asymptomatic
brother (II:4) at age 54 years showed that he
also had NCCM; with a NC/C ratio of 2.3
on echocardiography and a ratio of 2.9 on
CMR. No previous cardiac imaging had
been performed. He had elevated CK-levels
of 265 U/L without neuromuscular signs.
Ten years after the diagnosis NCCM he had
an episode of atrial fibrillation that required
electric cardioversion. CMR from the broth-
er (II:1) and the son (III:1) of the proband
were performed at age 57 and 15 years,
respectively, showing borderline NC/C
ratios of respectively 2.1 and 2.2 on MRI,
i.e. just below the diagnostic criteria.
Proband III-2 did not participate in the fam-
ily screening.
Family B
In family B (Figure 1B) the diagnosis
NCCM in a 17-year-old boy (III:1) was
made by echocardiography. He was referred
because of multiple unexplained episodes
of syncope. He also had a ventricular septal
defect (VSD) and a mild mitral valve pro-
lapse (MVP). CMR revealed partial LV
noncompaction from the apex to midven-
tricular region with an NC/C ratio of 3.0
(Figure 2C and D). An implantable car-
dioverter-defibrillator (ICD) was implanted.
After 9 years of follow-up, the LV function
remained normal without ICD shocks. CK-
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levels were elevated (419-1188 U/L) in the
absence of neuromuscular signs. His mother
(II:2) was under cardiologic surveillance
because she had a VSD, MVP, CoA and a
bicuspid aortic valve. The CMR showed
that she complied for the diagnostic criteria
for NCCM with a NC/C ratio of 2.4. She
had diastolic LV dysfunction, with pre-
served LV systolic function and underwent
multiple cardiac ablations for atrial fibrilla-
tion. At age 44 years she experienced severe
bradycardia, which necessitated cardiac
resuscitation, resulting from combined fle-
cainide and metoprolol treatment. A pace-
maker was implanted. Her highest CK-level
was 1174 U/L. The proband’s brother (III:2)
also suffered multiple episodes of syncope
and was diagnosed with NCCM at age 19,
with a NC/C ratio of 3.1 on CMR. His high-
est CK-level was 294U/l. Proband III-3 was
screened cardiologically and had no signs
of NCCM on echocardiography. No DNA
analysis was performed. 
Genetic testing
Diagnostic DNA NGS targeted testing
of a panel of 54 cardiomyopathy genes, that
did not include FLNC, as presented in Table
1, did not reveal a genetic causes for NCCM
in the two index cases. Also single-
nucleotide polymorphism-array DNA test-
ing showed no structural DNA changes.
Subsequently, whole exome sequencing
was performed in the NCCM patients II:1,
III:1 and III:3 from family A and III:1, III:2,
and II:2 from family B. Patients II-2 from
family B was included because we suspect-
ed that a causative mutation may underlie a
spectrum of cardiac phenotypes. Written
informed consent was obtained from all par-
ticipating family members. The investiga-
tion conforms to the principles outlined in
the Declaration of Helsinki. Variants were
annotated using ANNOVAR10 and filtered
using an in-house developed pipeline. Only
variants segregating within each family,
affecting exons or splice sites, with a popu-
lation frequency below 0.01 in ExAC, NFE,
GoNL were kept. For in silico prediction of
the effect of nonsynonymous variants we
used align GVGD,11 SIFT12 and Polyphen13
and ensemble scores LR and Radial SVM.14
We selected variants who were predicted to
be damaging by 3 of 5 prediction programs.
Segregating synonymous variants and vari-
ants predicted to be tolerated were exclud-
ed. In Family A, two candidate genes
remained after filtering, MYH4 and FLNC,
of which only the last was previously asso-
ciated with cardiomyopathy. A variant in
FLNC (c.6397C>T, p.(Arg2133Cys),
NM_001458.4, confirmed by sanger
sequencing) segregated with the cardiac
phenotype of NCCM in the three NCCM
patients and in the two relatives with bor-
derline NCCM features. A variant in the
same location (p.(Arg2133His)) was previ-
ously reported in a family with HCM and
classified as probably pathogenic.15 In fam-
ily B, a novel FLNC variant (c.7177C>T,
p.(Pro2393Ser)) was identified. The two
FLNC variants were absent in the Genome
Aggregation Database (http://gnomad.
broadinstitute.org), affect highly conserved
amino acids, and were predicted to be dele-
terious by multiple in silico prediction pro-
grams. No FLNC variants were found in
thirteen unrelated NCCM patients without a
CHD and without a pathogenic variant in 48
cardiomyopathy genes.
Histology 
Right ventricular endomyocardial biop-
sy (RVEMB) samples from the proband of
family B (III:1) were stained with hema-
toxylin and eosin as well as Masson’s
trichrome. To visualize protein aggregation
and autophagic activity in cardiomyocytes,
immunohistochemistry for microtubule-
associated protein 1A/1B-light chain 3
(LC3) was performed, as described previ-
ously.16 Light microscopic analysis showed
nonspecific cardiomyopathic changes of
myocyte hypertrophy and increased intersti-
tial fibrosis (Figure 3A). The RV did not
show an excessively thickened endocardial
layer or hypertrabeculation, or intracellular
aggregates or autophagic activity (Figure
3B).
Discussion and conclusions
This is the first report linking FLNC to
NCCM in two families with rare FLNC
variants. In these two families the cardiac
phenotype included NCCM, NCCM with
concurrent CoA, NCCM with concurrent
VSD and MPV and also a NCCM patient
with a complex CHD consisting of VSD,
MVP, CoA and bicuspid aortic valve, and
myocardial dysfunction. These observations
suggest that missense FLNC variants may
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Table 1. Diagnostic DNA NGS targeted testing of a panel of 54 cardiomyopathy genes (not including FLNC).
Diagnostic DNA panel
ABCC9, ACTC1, ACTN2, BAG3, CALR3, CASQ2, DES, DSC2, DSG2, DSP, DTNA, EMD, EYA4 FHL1, FKTN, GATAD1, GLA, HCN4, JPH2, JUP, LAMA4, LAMP2, LDB3, LMNA,
MIB1, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ1, MYOZ2, MYPN, NEBL, NEXN, NKX2-5, PKP2, PLN, PRDM16, RBM20, RYR2, SCN5A, TAZ, TBX20, TCAP,
TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR and VCL
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Figure 1. Pedigrees of families A and B. Pedigrees of NCCM families with missense FLNC
variants. Black filled symbols are affected family members. Gray filled symbols are family
members with hypertrabeculation not meeting NCCM criteria. The + sign indicates fam-
ily members carrying a FLNC likely pathogenic variant (p.(Arg2133Cys) in family A and
p.(Pro2393Ser) in family B. CM, cardiomyopathy; CoA, coarctation of the aorta; MVP,
mitral valve prolapse; NCCM, non-compaction cardiomyopathy; VSD, ventricular septal
defect.
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cause familial NCCM with or without one
or more structural heart defects. Missense
FLNC variants in the N and C terminal
domains of FLNC have been associated
with hypertrophic and restrictive cardiomy-
opathy, causing sarcomeric aggregates con-
taining FLNC leading to sarcomere dys-
function.15 Other FLNC domains were asso-
ciated with myofibrillar myopathy, showing
similar intracellular aggregates in skeletal
muscles.17,18 A large study of inherited car-
diovascular disease patients showed that
truncating FLNC variants were associated
predominantly with an overlapping pheno-
type of severe dilated- and arrhythmogenic
cardiomyopathies.8 The cardiomyopathy
phenotypes associated with FLNC variants
have not included NCCM so far, however
signs of LV hypertrabeculation not fulfilling
NCCM diagnosis in some carriers of a trun-
cating FLNC variants have been reported.8
FLNC has not been linked to CHD, sofar, to
the best of our knowledge.
Aortic coarctation in NCCM patients
seems rare with an estimated prevalence of
less than 1%.4 We report two families with
familial NCCM and a likely pathogenic
FLNC variant in which CoA occurred; in
one family one patient had NCCM with
concomitant CoA. In the other family a
NCCM patient with the familial FLNC vari-
ant had complex congenital cardiac defects
including a CoA. It remains to be elucidated
how FLNC and other genes can cause a car-
diomyopathy with or without a CHD, and
skeletal myopathy in other patients. It may
be that FLNC resembles MYH7 in that
aspect. Because among all the known genes
associated with cardiomyopathies as well as
skeletal myopathies, MYH7 variants occurs
the most frequent in NCCM, and is also
linked to Ebstein anomaly with and without
NCCM, HCM, DCM, or Laing distal
myopathy.19,20 Suggesting that variants
affecting distinct domains of sarcomeric
proteins may define the spectrum of cardiac
and skeletal muscle phenotypes. 
Pathogenic FLNC variants are expected
to disrupt the structure of the sarcomeric
protein, leading to the formation of protein
aggregates resulting in an impairment of the
sarcomere function.15,21 One of the identi-
fied variants in this study, FLNC
p.(Arg2133Cys), may have a similar effect
as the reported FLNC variant
p.(Arg2133His) at the same location with
another amino-acid substitution, that was
shown to have disrupting actin aggregates
in cardiac tissue.15 We found elevated CK
levels in two of the three NCCM patients in
both affected families. Elevated CK levels
were also noted in a previous study regard-
ing FLNC variants with myopathy but also
in patients with only a cardiac phenotype of
HCM.15 For the novel FLNC variant
p.(Pro2393Ser), we observed fibrosis in the
RV myocardium samples, indicating a dam-
aging effect of the variant on the cardiac
muscle. Fibrosis was also observed in previ-
ous reports with FLNC mutations.8,15 The
cardiac fibrosis observed in the patients
with the FLNC variant suggests that similar
pro-fibrotic mechanisms may be involved
as observed in MYBPC3 cardiomyopathy.22
Similarly, to the original report no signs of
intracellular aggregates or autophagic activ-
ity in the RV of the patient or in patients
with a FLNC related cardiomyopathy were
noted.8,15 The RV of this patient did not
show evidence for hypertrabeculation mor-
phologically or on imaging. However this
does not exclude an effect of the FLNC
variant on the left ventricle, since RV hyper-
trabeculation in NCCM is rarely reported,
and the NCCM presents predominantly
with a LV phenotype. 
As previous studies showed, genetics
plays an important role in approximately
half of the NCCM cases.23 The genetics of
NCCM are complex and affect mostly
genes associated with myopathies including
sarcomere or mitochondrial dysfunctioning.
In this perspective FLNC fits into the genet-
ically heterogeneous background of
NCCM. Further studies are needed to assess
the exact role and mechanisms of FLNC in
NCCM, aortic coarctation and mitral valve
abnormalities.
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Figure 2. Imaging of two NCCM patients. Family A. patient III.3; A) Short axis of the
left ventricle on cardiac magnetic resonance (CMR) showing the prominent trabeculae
and intertrabecular recesses in NCCM; B) Echocardiogram of the LV of patient (III.3)
with NCCM and excessive long chordae of the anterior mitral valve leaflet (arrow).
Family B. patient III.1; C) Two-chamber long-axis of the left ventricle on CMR; D) Short
axis view of the left ventricle on CMR showing the prominent trabeculae and intertrabec-
ular recesses in NCCM.
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ant carrier (Family B. III:1). A) Masson’s trichrome staining, original magnification x20,
shows mild fibrosis; B) Immunohistochemical staining (LC3), original magnification
x200, does not show protein aggregates with autophagic activity in cardiomyocytes. Faint
LC3 background cytoplasmic staining can be observed.No
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